Last reviewed · How we verify

Mometasone Furoate (MF)

Organon and Co · Phase 3 active Small molecule

Mometasone Furoate (MF) is a Topical corticosteroid Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Allergic rhinitis (nasal formulation). Also known as: SCH 032088, MK-0887, Nasonex®.

Mometasone furoate is a topical corticosteroid that suppresses local inflammatory and immune responses by binding to glucocorticoid receptors.

Mometasone furoate is a topical corticosteroid that suppresses local inflammatory and immune responses by binding to glucocorticoid receptors. Used for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Allergic rhinitis (nasal formulation).

At a glance

Generic nameMometasone Furoate (MF)
Also known asSCH 032088, MK-0887, Nasonex®
SponsorOrganon and Co
Drug classTopical corticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaDermatology, Allergy/Immunology
PhasePhase 3

Mechanism of action

Mometasone furoate is a synthetic glucocorticoid that exerts anti-inflammatory effects through glucocorticoid receptor activation, leading to reduced production of inflammatory mediators, decreased immune cell infiltration, and suppression of local inflammatory cascades. It is formulated for topical application to skin or nasal mucosa, providing localized therapeutic effects with minimal systemic absorption.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mometasone Furoate (MF)

What is Mometasone Furoate (MF)?

Mometasone Furoate (MF) is a Topical corticosteroid drug developed by Organon and Co, indicated for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Allergic rhinitis (nasal formulation).

How does Mometasone Furoate (MF) work?

Mometasone furoate is a topical corticosteroid that suppresses local inflammatory and immune responses by binding to glucocorticoid receptors.

What is Mometasone Furoate (MF) used for?

Mometasone Furoate (MF) is indicated for Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Allergic rhinitis (nasal formulation).

Who makes Mometasone Furoate (MF)?

Mometasone Furoate (MF) is developed by Organon and Co (see full Organon and Co pipeline at /company/organon-and-co).

Is Mometasone Furoate (MF) also known as anything else?

Mometasone Furoate (MF) is also known as SCH 032088, MK-0887, Nasonex®.

What drug class is Mometasone Furoate (MF) in?

Mometasone Furoate (MF) belongs to the Topical corticosteroid class. See all Topical corticosteroid drugs at /class/topical-corticosteroid.

What development phase is Mometasone Furoate (MF) in?

Mometasone Furoate (MF) is in Phase 3.

What are the side effects of Mometasone Furoate (MF)?

Common side effects of Mometasone Furoate (MF) include Local skin irritation or burning, Pruritus, Skin atrophy (with prolonged use), Headache (nasal formulation).

What does Mometasone Furoate (MF) target?

Mometasone Furoate (MF) targets Glucocorticoid receptor and is a Topical corticosteroid.

Related